253974
An Inside View of Federal Health Policy Making: The Robert Wood Johnson Health Policy Fellows
Monday, October 31, 2011: 1:50 PM
In 2007, I became the first RWJ health policy fellow to serve on the staff of the House Committee on Oversight and Government Reform, chaired by the time by Rep. Henry A. Waxman. During my service, I helped the Committee's professional staff with several high profile investigations and hearings, including an hearing on the FDA's role in evaluating the safety of Avandia, another on the Health and Environmental Impacts of Uranium Contamination in the Navajo Nation, and most notably, an extensive investigation of efforts to politicize the work of the Surgeon General of the U.S. Public Health Service. The experience convinced me of the need for health professionals, including physicians, to be more actively engaged in the policy process. After returning to my prior academic position to manage a concerted effort to keep Atlanta's only public hospital from closing, I joined the RAND Corporation as the Paul O'Neill-Alcoa Chair in Policy Analysis and now serve as Director of RAND Health, one of the world's largest and most influential organizations devoted to objective health policy research.
Learning Areas:
Public health or related laws, regulations, standards, or guidelines
Public health or related public policy
Learning Objectives: Inform participants of the existence of the RWJF Health Policy Fellowships, its history and purpose, and how to apply
Describe the typical fellow’s experience over the course of a year
Illustrate how fellows make a difference serving as Hill or Administration staffers
Convey the importance of the public health professionals engaging in the policymaking process through research, advocacy, staff work and service.
Presenting author's disclosure statement:Qualified on the content I am responsible for because: I am the VP and Director, RAND Health, RAND Corporation.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines,
and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed
in my presentation.
|